Ironwood Pharmaceuticals Inc (IRWD) Stock Price & Analysis
Ironwood Pharmaceuticals Inc (IRWD) fell 2.13% to USD 3.22 as of June 10, 2026 at 00:57 UTC, according to Nexqual real-time market data.
IRWD last closed at USD 3.29; the session ranged USD 3.15–3.39 on volume of 2,005,127 shares. Market capitalization is $530.06M, with a 52-week range of USD 0.58–5.78 (NMS). Source: Nexqual, June 10, 2026 at 00:57 UTC.
Key Statistics (as of June 10, 2026 at 00:57 UTC)
| Price | USD 3.22 |
|---|---|
| Change | ▼ 2.13% (down) |
| Previous Close | USD 3.29 |
| Open | USD 3.27 |
| Day Range | USD 3.15 – 3.39 |
| 52-Week Range | USD 0.58 – 5.78 |
| Volume | 2,005,127 shares |
| Market Cap | $530.06M |
| Exchange | NMS |
Technical Analysis (IRWD)
Nexqual's technical model rates IRWD "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.75 (neutral) |
| vs SMA50 | Below (USD 3.85) |
| MACD | -0.19 (negative) |
Analyst Ratings (IRWD)
Wall Street analysts rate IRWD "None" based on 4 analysts, with a mean price target of USD 6.1 (range USD 3.7–10), per Nexqual as of June 10, 2026 at 00:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 6.1 |
| High Target | USD 10 |
| Low Target | USD 3.7 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (IRWD)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.28 |
| Revenue Estimate | $117.60M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.24 vs est 0.24 ▲ beat |
| 2025-12-31 | USD -0.01 vs est 0.01 ▼ miss |
| 2025-09-30 | USD 0.24 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.14 vs est 0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Financials & Fundamentals (IRWD)
| Total Revenue | $361.51M |
|---|---|
| Revenue Growth (YoY) | +158.90% |
| Gross Margin | +75.20% |
| Operating Margin | +68.10% |
| Profit Margin | +28.26% |
| Current Ratio | 1.41 |
| Total Cash | $220.47M |
| Total Debt | $597.36M |
| Free Cash Flow | $51.16M |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Financial Health Score (IRWD)
Nexqual rates Ironwood Pharmaceuticals Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:57 UTC.
| Growth | Critical — Revenue -16% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 68% |
| Balance Sheet | Mixed — $220M cash vs $597M debt |
| Cash Flow | Strong — FCF $51M, 17% margin |
| Efficiency | Mixed — No data |
Ownership (IRWD)
| Insider Ownership | +2.93% |
|---|---|
| Institutional Ownership | +98.30% |
| Shares Outstanding | 164.61M |
| Float | 135.35M |
| Short % of Float | +11.51% |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Leadership (IRWD)
Ironwood Pharmaceuticals Inc is led by Thomas A. McCourt (age 68), CEO & Director, per Nexqual as of June 10, 2026 at 00:57 UTC.
| CEO & Director | Thomas A. McCourt (age 68) |
|---|---|
| Senior Vice President & Chief Commercial Officer. | Tammi Gaskins (age 52) |
| Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Ronald Silver (age 43) |
| Chief Strategy Officer | Jeff Ruberti |
Major Backers & Investors (IRWD)
Notable institutional backers of Ironwood Pharmaceuticals Inc include Armistice Capital, LLC, Sarissa Capital Management, LP, Bank of America Corporation, according to Nexqual as of June 10, 2026 at 00:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.13% |
| Sarissa Capital Management, LP | 5.58% |
| Bank of America Corporation | 5.27% |
| Renaissance Technologies | 4.9% |
| AQR Capital Management, LLC | 4.58% |
| Acadian Asset Management. LLC | 4% |
| Charles Schwab | 1.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.8% |
| BlackRock | 11.17% |
| State Street | 7.23% |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
From Ironwood Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
- It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
- The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease.
- It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INVA | Innoviva, Inc. | USD 22.54 | ▲ 0.09% |
| ENTA | Enanta Pharmaceuticals, Inc. | USD 11.35 | ▲ 0.62% |
| PCRX | Pacira BioSciences, Inc. | USD 23.21 | ▲ 2.02% |
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| COLL | Collegium Pharmaceutical, Inc. | USD 34.4 | ▲ 3.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:57 UTC. This page is informational and not investment advice.